Calcitonin gene-related peptide (CGRP) and its role in hypertension

Neuropeptides

Volumn 45, Issue 2, 2011, Pages 93-104

  Smillie, Sarah Jane ^a   Brain, Susan D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CLR; Human; Hypertension; Mouse; RAMP1; Rat; Sensory nerves; TRPV1

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE[8-37]; CALCITONIN RECEPTOR LIKE RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLCEGEPANT; RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; TELCAGEPANT;

AMINO ACID SUBSTITUTION; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN STEM; CLINICAL TRIAL (TOPIC); DIMERIZATION; DNA MODIFICATION; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; KNOCKOUT MOUSE; LIFESTYLE; MIGRAINE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSORY NERVE; VASODILATATION;

ANIMALIA; RATTUS;

EID: 79951513390     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.12.002     Document Type: Review

References (148)

1. Aiyar N., Rand K., Elshourbagy N.A., Zeng Z., Adamou J.E., Bergsma D.J., Li Y. A cDNA encoding the calcitonin gene-related peptide type 1 receptor. J. Biol. Chem. 1996, 271:11325-11329.
2. Alevizaki, M., Shiraishi, A., Rassool, F.V., Ferrier, G.J., MacIntyre, I., Legon, S. 1986.The calcitonin-like sequence of the beta CGRP gene. FEBS Lett. 206, 47-52.
3. Amara S.G., Jonas V., Rosenfeld M.G., Ong E.S., Evans R.M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982, 298:240-244.
4. Ando K., Pegram B.L., Frolich E.D. Hemodynamic effects of calcitonin gene-related peptide in spontaneously hypertensive rats. Am. J. Physiol. 1990, 258:R425-R429.
5. Bennett G.S., Garrett N.E., Diemel L.T., Brain S.D., Tomlinson D.R. Neurogenic cutaneous vasodilatation and plasma extravasation in diabetic rats: effect of insulin and nerve growth factor. Br. J. Pharmacol. 1998, 124:1573-1579.
6. Bowers M.C., Katki K.A., Rao A., Koehler M., Patel P., Spiekerman A., DiPette D.J., Supowit S.C. Role of calcitonin gene-related peptide in hypertension-induced renal damage. Hypertension 2005, 46:51-57.
7. Brain S.D., Williams T.J. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br. J. Pharmacol. 1985, 86:855-860.
8. Brain S.D., Tippins J.R., Morris H.R., MacIntyre I., Williams T.J. Potent vasodilator activity of calcitonin gene-related peptide in human skin. J. Invest. Dermatol. 1986, 87:533-536.
9. Brain S.D., Grant A.D. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 2004, 84:903-934.
10. Brain S.D., Cox H.M. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br. J. Pharmacol. 2006, 147:202-211.
11. Branca, F., Nikogosian, H., Lobstein, T. 2007. The challenge of obesity in the WHO European Region and the Strategies for Response.
12. Bühlmann N., Aldecoa A., Leuthäuser K., Gujer R., Muff R., Fischer J.A., Born W. Glycosylation of the calcitonin receptor-like receptor at Asn(60) or Asn(112) is important for cell surface expression. FEBS Lett. 2000, 486:320-324.
13. Burg M., Zahm D.S., Knuepfer M.M. Intrathecal capsaicin enhances one-kidney renal wrap hypertension in the rat. J. Auton. Nerv. Syst. 1994, 50:180-199.
14. Carpenter K.A., Schmidt R., von Mentzer B., Haglund U., Roberts E., Walpole C. Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains. Biochemistry 2001, 40:8317-8325.
15. Chai W., Mehrotra S., Jan Danser A.H., Schoemaker R.G. The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts. Eur. J. Pharmacol. 2006, 531:246-253.
16. Chan K., Edvinsson L., Eftekhari S., Kimblad P.O., Kane S., Lynch J., Hargreaves R., de Vries R., Garrelds I., van den Bogaerdt A., Danser J., Maassenvandenbrink A. Characterization of the CGRP receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J. Pharmacol. Exp. Ther. 2010, 334:746-752.
17. Chiba T., Yamaguchi A., Yamatani T., Nakamura A., Morishita T., Inui T., Fukase M., Noda T., Fujita T. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am. J. Physiol. 1989, 256:E331-E335.
18. Conner A.C., Hay D.L., Howitt S.G., Kilk K., Langel U., Wheatley M., Smith D.M., Poyner D.R. Interaction of calcitonin-gene-related peptide with its receptors. Biochem. Soc. Trans. 2002, 30:451-455.
19. Crossman D.C., Dashwood M.R., Brain S.D., McEwan J., Pearson J.D. Action of calcitonin gene-related peptide upon bovine vascular endothelial and smooth muscle cells grown in isolation and co-culture. Br. J. Pharmacol. 1990, 99:71-76.
20. Deng P.Y., Li Y.J. Calcitonin gene-related peptide and hypertension. Peptides 2005, 26:1676-1685.
21. Dennis T., Fournier A., Cadieux A., Pomerleau F., Jolicoeur F.B., St Pierre S., Quirion R. HCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J. Pharmacol. Exp. Ther. 1990, 254:123-128.
22. Ditting T., Tiegs G., Rodionova K., Reeh P.W., Neuhuber W., Freisinger W., Veelken R. Do distinct populations of dorsal root ganglion neurons account for the sensory peptidergic innervation of the kidney? Am. J. Physiol. Renal Physiol. 2009, 297:F1427-F1434.
23. Djoussé L., Mukamal K.J. Alcohol consumption and risk of hypertension: does the type of beverage or drinking pattern matter?. Revista Española De Cardiología 2009, 62:603-605.
24. Doods H., Hallermayer G., Wu D., Entzeroth M., Rudolf K., Engel W., Eberlein W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 2000, 129:420-423.
25. Edvinsson L., Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010, 376:645-655.
26. Edvinsson L., Chan K.Y., Eftekhari S., Nilsson E., De Vries R., Saveland H., Dirven C.M.F., Danser A.H.J., MaassenVanDenBrink A. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 2010, 30:1233-1240.
27. Edvinsson L., Uddman E., Wackenfors A., Davenport A., Longmore J., Malmsjo M. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin. Sci. (Lond) 2005, 109:335-342.
28. Edvinsson L., Gulbenkian S., Barroso C.P., Cunha M., Polak J.M., Mortensen A., Jorgensen L., Jansen-Olsen I. Innervation of the human middle meningeal artery: Immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 1998, 19:1213-1225.
29. Edvinsson L., Erlinge D., Ekman R., Thulin T. Sensory nerve activity in sever hypertension as reflected by circulating calcitonin gene-related peptide (CGRP) and substance P. Blood Press. 1992, 1:223-229.
30. Edvinsson L., Ekman R., Thulin T. Circulating perivascular dilatory neuropeptides in hypertension. J. Hypertens. 1989, 7:194-195.
31. Edvinsson L., Fredholm B.B., Hamel E., Jansen I., Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci. Lett. 1985, 58:213-217.
32. Félétou M., Vanhoutte P.M. Endothelium-derived hyperpolarizing factor: where are we now?. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1215-1225.
33. Fernandes E.S., Schmidhuber S.M., Brain S.D. Sensory-nerve-derived neuropeptides: possible therapeutic targets. Handb. Exp. Pharmacol. 2009, 194:393-416.
34. Fisher L.A., Kikkawa D.O., Rivier J.E., Amara S.G., Evans R.M., Rosenfeld M.G., Vale W.W., Brown M.R. Stimulation of noradrenergic sympathetic outflow by calcitonin gene- related peptide. Nature 1983, 305:534-536.
35. Flahaut M., Pfister C., Rossier B.C., Firsov D. N-glycosylation and conserved cysteine residues in RAMP3 play a critical role for the functional expression of CLR/RAMP3 adrenomedullin receptor. Biochemistry 2003, 42:10333-10341.
36. Fluhmann B., Muff R., Hunziker W., Fischer J.A., Born W. A human orphan calcitonin receptor-like structure. Biochem. Biophys. Res. Commun. 1995, 206:341-347.
37. Fraser N.J., Wise A., Brown J., McLatchie L.M., Main M.J., Foord S.M. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol. Pharmacol. 1999, 55:1054-1059.
38. Frezza E.E., Wei C., Wachtel M.S. Is surgery the next answer to treat obesity-related hypertension?. J. Clin. Hypertens. 2009, 11:284-288.
39. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 27:373-376.
40. Gangula P.R.R., Zhao H., Supowit S.C., Wimalawansa S.J., Dipette D.J., Westlund K.N., Gagel R.F., Yallampalli C. Increased Blood Pressure inα-Calcitonin Gene-Related Peptide/Calcitonin Gene Knockout Mice. Hypertension 2000, 35:470.
41. Gangula P.R.R., Zhao H., Supowit S., Wimalawansa S., DiPette D., Yallampalli C. Pregnancy and steroid hormones enhance the vasodilation responses to CGRP in rats. Am. J. Physiol. Heart. Circ. Physiol. 1999, 276:H284-H288.
42. Gangula P.R., Supowit S.C., Wimalawansa S.J., Zhao H., Hallman D.M., DiPette D.J., Yallampalli C. Calcitonin gene-related peptide is a depressor in NG-nitro-L-arginine methyl ester-induced hypertension during pregnancy. Hypertension 1997, 29:248-253.
43. Gardiner S.M., Compton A.M., Kemp P.A., Bennett T., Bose C., Foulkes R., Hughes B. Antagonistic effect of human alpha-calcitonin gene-related peptide (8-37) on regional hemodynamic actions of rat islet amyloid polypeptide in conscious Long-Evans rats. Diabetes 1991, 40:948-951.
44. Gennari C., Fischer J.A. Cardiovascular action of calcitonin gene-related peptide in humans. Calcif. Tissue Int. 1985, 37:581-584.
45. Geppetti P., Holzer P. Neurogenic Inflammation 1996, CRC Press, Boca Raton.
46. Goadsby P.J., Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994, 117:427-434.
47. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 1993, 33:48-56.
48. Goadsby P.J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Nerol. 1990, 28:183-187.
49. Goadsby P.J., Edvinsson L., Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 1988, 23:193-196.
50. Goodman E.C., Iversen L.L. Calcitonin gene-related peptide: novel neuropeptide. Life Sci. 1986, 38:2169-2178.
51. Gujer R., Aldecoa A., Buhlmann N., Leuthauser K., Muff R., Fischer J.A., Born W. Mutations of the asparagine117 residue of a receptor activity-modifying protein 1-dependent human calcitonin gene-related peptide receptor result in selective loss of function. Biochemistry 2001, 40:5392-5398.
52. Gupta P., Harte A., Sturdee D.W. Effects of menopausal status on circulating calcitonin gene-related peptide and adipokines: implications for insulin resistance and cardiovascular risks. Climacteric 2008, 11:364-372.
53. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
54. Hay D.L. What makes a CGRP2 receptor?. Clin. Exp. Pharmacol. Physiol. 2007, 34:963-971.
55. Hay D.L., Conner A.C., Howitt S.G., Smith D.M., Poyner D.R. The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors. J. Mol. Neurosci. 2004, 22:105-113.
56. Holzer P. Peptidergic sensory neurons in the control of vascular functions: mechanisms and significance in the cutaneous and splanchnic vascular beds. Rev. Physiol. Biochem. Pharmacol. 1992, 121:49-146.
57. Howitt S.G., Kilk K., Wang Y., Smith D.M., Langel U., Poyner D.R. The role of the 8-18 helix of CGRP8-37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. Br. J. Pharmacol. 2003, 138:325-332.
58. Itabashi A., Kashiwabara H., Shibuya M., Tanaka K., Masaoka H., Katayama S., Ishii J. The interaction of calcitonin gene-related peptide with angiotensin II on blood pressure and renin release. J. Hypertens. Suppl. 1988, 6:S418-S420.
59. 69of thecalcitonin-like receptoris required for its functional expression together withreceptor-activity-modifying proteins1 and -2. Biochem. Biophys. Res. Commun. 2004, 319:1203-1209.
60. Izzo J.L., Sica D.A., Black H.R. Hypertension Primer: The Essentials of High Blood Pressure, Basic Science, population science and clinical management. 4th Edition 2008, American Heart Association, Dallas, Texas.
61. Juhasz G., Zsombok T., Modos E.A., Olajos S., Jakab B., Nemeth J., Szolcsanyi J., Vitrai J., Bagdy G. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003, 106:461-470.
62. Kallner G. Release and effects of calcitonin gene-related peptide in myocardial ischaemia. Scand. Cardiovasc. J. Suppl. 1998, 49:1-35.
63. Kawasaki H. Regulation of vascular function by perivascular calcitonin gene-related peptide-containing nerves. Jpn. J. Pharmacol. 2002, 88:39-43.
64. Kawasaki T., Itoh K., Kawasaki M. Reduction in blood pressure with a sodium-reduced, potassium- and magnesium-enriched mineral salt in subjects with mild essential hypertension. Hypertens. Res. 1998, 21:235-243.
65. Kawasaki H., Takasaki K., Saito A., Goto K. Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature 1988, 335:164-167.
66. Kirkby N.S., Hadoke P.W., Bagnall A.J., Webb D.J. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?. Br. J. Pharmacol. 2008, 153:1105-1119.
67. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 1993, 192:553-560.
68. Kittur S.D., Hoppener J.W., Antonarakis S.E. Linkage map of the short arm of human chromosome 11: location of the genes for catalase, calcitonin, and insulin-like growth factor II. Proc. Natl. Acad. Sci. USA 1985, 82:5064-5067.
69. Kjartansson J., Dalsgaard C.J. Calcitonin gene-related peptide increases survival of a musculocutaneous critical flap in the rat. Eur. J. Pharmacol. 1987, 142:355-358.
70. Köhler R., Hoyer J. The endothelium-derived hyperpolarizing factor: insights from genetic animal models. Kidney Int. 2007, 72:145-150.
71. Kurihara H., Shindo T., Oh-Hashi Y., Kurihar Y., Kuwaki T. Targeted disruption of adrenomedullin and alphaCGRP genes reveals their distinct biological roles. Hypertens. Res. 2003, 26:105-108.
72. Kuwasako K., Kitamura K., Nagoshi Y., Cao Y.-N., Eto T. Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J. Biol. Chem. 2003, 278:22623-22630.
73. Kyrou I., Chrousos G.P., Tsigos C. Stress, visceral obesity, and metabolic complications. Ann. N. Y. Acad. Sci. 2006, 1083:77-110.
74. Lackland D.T., Egan B.M. Dietary salt restriction and blood pressure in clinical trials. Curr. Hypertens. Rep. 2007, 9:314-319.
75. Lemne C.E., Lundeberg T., Theodorsson E., Faire U. Increased basal concentrations of plasma endothelin in borderline hypertension. J. Hypertens. 1994, 12:1069-1074.
76. Li D., Chen B.M., Peng J., Zhang Y.S., Li X.H., Yuan Q., Hu C.P., Deng H.W., Li Y.J. Role of anandamide transporter in regulating calcitonin gene-related peptide production and blood pressure in hypertension. J. Hypertens. 2009, 27:1224-1232.
77. Li D., Peng J., Xin H.Y., Luo D., Zhang Y.S., Zhou Z., Jiang D.J., Deng H.W., Li Y.J. Calcitonin gene-related peptide-mediated antihypertensive and anti-platelet effects by rutaecarpine in spontaneously hypertensive rats. Peptides 2008, 29:1781-1788.
78. Li J., Zhao H., Supowit S., DiPette D., Wang D. Activation of the renin-angiotensin system in α-calcitonin gene-related peptide/calcitonin gene knockout mice. J. Hypertens. 2004, 22:1345-1349.
79. Lin H.Y., Harris T.L., Flannery M.S., Aruffo A., Kaji E.H., Gorn A., Kolakowski L.F., Lodish H.F., Goldring S.R. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 1991, 254:1022-1024.
80. Lind H., Edvinsson L. Enhanced vasodilator responses to calcitonin gene-related peptode (CGRP) in subcutaneous arteries in human hypertension. J. Hum. Hypertens. 2002, 16:53-59.
81. Lind H., Brudlin L., Lindholm L., Edvinsson L. Different levels of sensory neuropeptides (calcitonin gene-related peptide and substance P) during and after exercise in man. Clin. Physiol. 1996, 16:73-82.
82. Lindstedt I.H., Edvinsson M.L., Edvinsson L. Reduced responsiveness of cutaneous microcirculation in essential hypertension-a pilot study. Blood Press. 2006, 15:275-280.
83. Lu J.T., Son Y.J., Lee J., Jetton T.L., Shiota M., Moscoso L., Niswender K.D., Loewy A.D., Magnuson M.A., Sanes J.R., Emeson R.B. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol. Cell. Neurosci. 1999, 14:99-120.
84. Lundberg J.M., Franco-Cereceda A., Hua X., Hökfelt T., Fischer J.A. Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur. J. Pharmacol. 1985, 108:315-319.
85. Maggi C.A. The pharmacology of the efferent function of sensory nerves. J. Auton. Pharmacol. 1991, 11:173-208.
86. Maggi C.A. Capsaicin-sensitive nerves in the gastrointestinal tract. Arch. Int. Pharmacodyn. Ther. 1990, 303:157-166.
87. Maggi C.A., Meli A. The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen. Pharmacol. 1988, 19:1-43.
88. Mallee J.J., Salvatore C.A., LeBourdelles B., Oliver K.R., Longmore J., Koblan K.S. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J. Biol. Chem. 2002, 277:14294-14298.
89. Manrique C., Lastra G., Gardner M., Sowers J.R. The renin angiotensin aldosterone system in hypertension:role of insulin resistance and oxidative stress. The Medical Clinics of North America 2009, 93:569-582.
90. Manzini S., Bacciarelli C. Enhanced development of deoxycorticosterone-induced hypertension in neonatally capsaicin-pretreated rats. Regul. Pept. 1988, 22:119.
91. Márquez-Rodas I., Longo F., Rothlin R.P., Balfagón G. Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension. J. Physiol. Biochem. 2006, 62:45-56.
92. Masuda A., Shimamoto K., Mori Y., Nakagawa M., Ura N., Iimura O. Plasma calcitonin gene-related peptide levels in patients with various hypertensive diseases. J. Hypertens. 1992, 10:1499-1504.
93. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., Solari R., Lee M.G., Foord S.M. RAMPs regulate the transport and ligand specificity of the calcitonin- receptor-like receptor. Nature 1998, 393:333-339.
94. Meens M.J., Fazzi G.E., van Zandvoort M.A., De Mey J.G. Calcitonin gene-related peptide selectively relaxes contractile responses to endothelin-1 in rat mesenteric resistance arteries. J. Pharmacol. Exp. Ther. 2009, 331:87-95.
95. Moncada S., Needleman P., Bunting S., Vane J.R. Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins 1976, 12:323-335.
96. Mulderry P.K., Ghatei M.A., Spokes R.A. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 1988, 25:195-205.
97. Mulvany M.J., Aalkjaer C. Structure and function of small arteries. Physiol. Rev. 1990, 70:921-961.
98. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update of NICE Clinical Guideline 18, number 34. 34. 2006, National Institute for Health and Clinical Excellence, London, Royal College of Physicians.
99. Nelson M.T., Huang Y., Brayden J.E., Hescheler J., Standen N.B. Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature 1990, 344:770-773.
100. Oh-hashi Y., Shindo T., Kurihara Y., Imai T., Wang Y., Morita H., Imai Y., Kayaba Y., Nishimatsu H., Suematsu Y., Hirata Y., Yazaki Y., Nagai R., Kuwaki T., Kurihara H. Elevated sympathetic nervous activity in mice deficient in alphaCGRP. Circ. Res. 2001, 89:983-990.
101. Olesen J., Diener H.-C., Husstedt I.W., Goadsby P.J., Hall D., Meier U., Pollentier S., Lesko L.M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 2004, 350:1104-1110.
102. Oliver K.R., Wainwright A., Edvinsson L., Pickard J.D., Hill R.G. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J. Cereb. Blood Flow Metab. 2002, 22:620-629.
103. Oparil S., Zaman M.A., Calhoun D.A. Pathogenesis of hypertension. Ann. Intern. Med. 2003, 139:761-776.
104. Opitz C.F., Ewert R. Dual ET(A)/ET(B) vs. Selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur. J. Clin. Invest. 2006, 36:1-9.
105. Peng J., Li Y.J. The vanilloid receptor TRPV1: role in cardiovascular and gastrointestinal protection. Eur. J. Pharmacol. 2010, 10:1-7.
106. Petermann J.B., Born W., Chang J.Y., Fischer J.A. Identification in the human central nervous system, pituitary, and thyroid of a novel calcitonin gene-related peptide, and partial amino acid sequence in the spinal cord. J. Biol. Chem. 1987, 262:542-545.
107. Pimenta E., Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vascular Health and Risk Management 2009, 5:453-463.
108. Portaluppi F., Vergnani L., degli Uberti E.C. Atrial natriuretic peptide and circadian blood pressure regulation: clues from a chronobiological approach. Chronobiol. Int. 1993, 10:176-189.
109. Portaluppi F., Trasforini G., Margutti A., Vergnani L., Ambrosio M.R., Rossi R. Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J. Hypertens. 1992, 10:1277-1284.
110. Poyner D.R., Sexton P.M., Marshall I., Smith D.M., Quirion R., Born W. International Union of Pharmacology:XXXII. The mammalian calcitonin gene-related peptides, AM, AMY, and calcitonin receptors. Pharmacol. Rev. 2002, 54:233-246.
111. Preibisz J.J. Calcitonin gene-related peptide and regulation of human cardiovascular homeostasis. Am. J. Hypertens. 1993, 6:434-450.
112. Qi T., Hay D.L. Structure-function relationships of the N-terminus of receptor activity-modifying proteins. Br. J. Pharmacol. 2010, 159:1059-1068.
113. Quirion R., Van Rossum D., Dumont Y., St Pierre S., Fournier A. Characterization of CGRP1 and CGRP 2 receptor subtypes. Ann. N. Y. Acad. Sci. 1992, 657:88-105.
114. Regan C.P., Stump G.L., Kane S.A., Lynch J.J. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischaemia during atrial pacing in dogs with coronary artery stenosis. J. Pharmacol. Exp. Ther. 2009, 328:571-578.
115. Roh J., Chang C.L., Bhalla A., Klein C., Hsu S. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. The Journal of Biological Chemistry 2003, 279:7264-7274.
116. Rovero P., Giuliani S., Maggi C.A. CGRP antagonist activity of short C-terminal fragments of human alpha CGRP, CGRP(23-37) and CGRP(19-37). Peptides 1992, 13:1025-1027.
117. Russo A.F. Ramping it up: RAMP1 and the implications for migraine. Pharmacogenomics 2007, 8:687-690.
118. Sabharwal R., Zhang Z., Lu Y., Abboud F.M., Russo A.F., Chapleau M.W. Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-induced hypertension. Hypertension 2010, 55:627-635.
119. Schifter S., Krusell L.R., Sehested J. Normal serum levels of calcitonin gene-related peptide (CGRP) in mild to moderate essential hypertension. Am. J. Hypertens. 1991, 4:565-569.
120. Schneider M.P., Inscho E.W., Pollock D.M. Attenuated vasoconstrictor responses to endothelin in afferent arterioles during a high-salt diet. Am. J. Physiol. Renal Physiol. 2007, 292:1208-1214.
121. Sexton P.M., Poyner D.R., Simms J., Christopoulos A., Hay D.L. Modulating receptor function through RAMPs:can they represent drug targets in themselves? Drug Discov. Today 2009, 14:413-419.
122. Simms J., Hay D.L., Bailey R.J., Konycheva G., Bailey G., Wheatley M. Structure function analysis of RAMP1 by alanine mutagenesis. Biochemistry 2009, 41:11398-11401.
123. Steenbergh P.H., Höppener J.W., Zandberg J. Structure and expression of the human calcitonin/CGRP genes. FEBS Lett. 1986, 209:97-103.
124. Steiner S., Born W., Fischer J.A., Muff R. The function of conserved cysteine residues in the extracellular domain of human receptor-activity-modifying protein. FEBS Lett. 2003, 555:285-290.
125. Steiner S., Muff R., Gujer R., Fischer J.A., Born W. The transmembrane domain of receptor-activity-modifying protein 1 is essential for the functional expression of a calcitonin gene-related peptide receptor. Biochemistry 2002, 41:11398-11404.
126. Supowit S.C., Zhao H., Hallman D.M., DiPette D.J. Calcitonin gene-related peptide is a depressor of deoxycorticosterone-salt hypertension in the rat. Hypertension 1997, 29:945-950.
127. Susic D., Frohlich E.D. The aging hypertensive heart: a brief update. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:104-110.
128. Tang J.A., Xu D., Yuan Q.X., Meng Z.H., Cheng F.R., Chen M.Z., Liu G.Z., Liu L.S., Zhang Z.K. Calcitonin gene-related peptide in the pathogenesis and treatment of hypertension. Chin. Med. J. (Engl). 1989, 102:897-901.
129. Tatasciore A., Renda G., Zimarino M., Soccio M., Bilo G., Parati G., Schillaci G., De Caterina R. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007, 50:325-332.
130. Thomas D.A., Dubner R., Ruda M.A. Neonatal capsaicin treatment in rats results in scratching behavior with skin damage: potential model of non-painful dysesthesia. Neurosci. Lett. 1994, 171:101-104.
131. Tsujikawa K., Yayama K., Hayashi T., Matsushita H., Yamaguchi T., Shigeno T., Ogitani Y., Hirayama M., Kato T., Fukada S., Takatori S., Kawasaki H., Okamoto H., Ikawa M., Okabe M., Yamamoto H. Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc. Natl. Acad. Sci. U S A. 2007, 104:16702-16707.
132. Uchiyamam A., Shimizu T., Nakagawa T., Tanaka T. Association of hypertension with changes in the body mass index of university students. Environ. Health. Prev. Med. 2008, 13:271-280.
133. Udawela M., Christopoulos G., Morfis M., Christopoulos A., Ye S.Y., Tilakartne N. A critical role for the short intracellular C terminus in receptor activity-modifying protein function. Mol. Pharmacol. 2006, 70:1750-1760.
134. Uddman R., Edvinsson L., Ekblad E., Hakanson R., Sundler F. Calcitonin gene-related peptide (CGRP); perivascular distribution and vasodilatory effects. Regul. Pept. 1986, 15:1-23.
135. Uren N.G., Seydoux C., Davies G.J. Effect of intravenous calcitonin gene related peptide on ischaemia threshold and coronary stenosis severity in humans. Cardiovasc. Res. 1993, 27:1477-1481.
136. Wang H., Xing L., Li W., Hou L., Guo J., Wang X. Production and secretion of calcitonin gene-related peptide from human lymphocytes. J. Neuroimmunol. 2002, 130:155-162.
137. Wang D.H. The vanilloid receptor and hypertension. Acta. Pharmacol. Sin. 2005, 26:286-294.
138. Wang B., Zhang J.D., Wang S.H. Effects of Qindan Capsule on blood pressure, endothelin, calcitonin gene-related peptide and angiotensin- II in spontaneous hypertensive rats. Chin. J. Integr. Med. 2006, 12:287-291.
139. Wang Z.G., Liu J.L., Liu Y., Wen S.J., Wen J., Liu Y.P., Chen X.J., Wu Z.S. Increased plasma vasoactive substances and antioxidant enzymes levels in prehypertensive patients. Zhonghua Xin Xue Guan Bing Za Zhi. 2007, 35:719-722.
140. Westermark P., Wernstedt C., Wilander E., Sletten K. A novel peptide in the calcitonin gene relate peptide family as an ahyloid fibril protein in the endocrine pancrrab. Biochem. Biophys. Res. Commun. 1986, 140:827-831.
141. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., Sever P.S., MCG T.S. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society. J. Hum. Hypertens. 2004, 18:139-185.
142. Wimalawansa S.J., Morris H.R., Etienne A. Isolation, purification and characterization of beta-hCGRP from human spinal cord. Biochem. Biophys. Res. Commun. 1990, 167:993-1000.
143. Wimalawansa S.J. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potential. Endoc. Rev. 1996, 17:533-585.
144. Wofford M.R., Hall J.E. Pathophysiology and treatment of obesity hypertension. Curr. Pharm. Des. 2004, 10:3621-3637.
145. Wu D., Eberlein W., Rudolf K., Engel W., Hallermayer G., Doods H. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor. Eur. J. Pharmacol. 2000, 400:313-319.
146. Wyon Y., Frisk J., Lundeberg T., Theodorsson E., Hammar M. Postmenopausal women with vasomotor symptoms have increased urinary excretion of calcitonin gene-related peptide. Maturitas 1998, 30:289-294.
147. Zimmerman B.G. Peripheral neurogenic factors in acute and chronic alterations of arterial pressure. Circ. Res. 1983, 53:121-130.
148. Zumpe E.T., Tilakaratne N., Fraser N.J., Christopoulos G., Foord S.M., Sexton P.M. Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product. Biochem. Biophys. Res. Commun. 2000, 267:368-372.